VX-166

• UNSPSC Description:

  VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver[1].

• Target Antigen:

  Caspase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/vx-166.html

• Smiles:

  FC(C(F)=CC(F)=C1F)=C1OCC([C@H](CC(O)=O)NC([C@@H](N2C(C(NC(OC)=O)=CC=C2)=O)CC)=O)=O

• Molecular Weight:

  531.41

• References & Citations:

  [1]John Pollard, et al. Treatment of liver diseases with a caspase inhibitor. Patent WO2010120880A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  800408-39-3